Tissue factor is the major initiator of coagulation. Both factor IX and factor X are activated by the complex of factor Vlla and tissue factor (Vlla/TF). The goal of this study was t o determine the specific roles of factors IXa and Xa in initiating coagulation. We used a model system of in vitro coagulation initiated by Vlla/TF and that included unactivated platelets and plasma concentrations of factors II, V, VIII, IX, and X, tissue factor pathway inhibitor, and antithrombin 111. In some cases, factor IX and/or factor X were activated by tissue factor-bearing monocytes, but in some experiments, picomolar concentrations of preactivated factor IX or factor X were used t o initiate the reactions. Timed samples were assayed for both platelet activation and thrombin activity. Factor Xa was 10 times more potent than factor IXa in initiating platelet activation, but factor IXa was much more effective in promoting thrombin generation than was factor Xa. In the presence of Vlla/TF, factor X was required for both platelet activation and thrombin generation, while factor IX E XPOSURE O F blood to tissue factor is the major physiologic stimulus to initiate coagulation.' Coagulation factor VIIa associates with tissue factor, and the complex activates both factor X and factor IX.' Activated factor X (Xa) reacts with and is inhibited by tissue factor pathway inhibitor (TFPI). The TFPVXa complex then inhibits the VIIa/TF complex.3s4 Thus, in order for coagulation to occur, sufficient amounts of procoagulant factors must be generated during a limited period of time when the VIIa/TF complex is active. The regulation of tissue factor exposure and activity is crucial to controlling initiation of coagulation. Even though platelets provide the major procoagulant surface for hemostasis, they do not express tissue factor and, therefore, cannot initiate the process. Activated coagulation factors produced at the site of VIJa/TF activity must find their way to the platelet surface to effectively propagate coagulation. Thus, induction of coagulation by tissue factor is a complex process. Its success or failure is governed by spatial, temporal, and quantitative features of factor IXa and factor Xa generation (ie, where, when, and how much factor is activated). The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this facf.
Tissue factor is the major initiator of coagulation. Both factor IX and factor X are activated by the complex of factor Vlla and tissue factor (Vlla/TF). The goal of this study was t o determine the specific roles of factors IXa and Xa in initiating coagulation. We used a model system of in vitro coagulation initiated by Vlla/TF and that included unactivated platelets and plasma concentrations of factors II, V, VIII, IX, and X, tissue factor pathway inhibitor, and antithrombin 111. In some cases, factor IX and/or factor X were activated by tissue factor-bearing monocytes, but in some experiments, picomolar concentrations of preactivated factor IX or factor X were used t o initiate the reactions. Timed samples were assayed for both platelet activation and thrombin activity. Factor Xa was 10 times more potent than factor IXa in initiating platelet activation, but factor IXa was much more effective in promoting thrombin generation than was factor Xa. In the presence of Vlla/TF, factor X was required for both platelet activation and thrombin generation, while factor IX E XPOSURE O F blood to tissue factor is the major physiologic stimulus to initiate coagulation.' Coagulation factor VIIa associates with tissue factor, and the complex activates both factor X and factor IX.' Activated factor X (Xa) reacts with and is inhibited by tissue factor pathway inhibitor (TFPI). The TFPVXa complex then inhibits the VIIa/TF complex.3s4 Thus, in order for coagulation to occur, sufficient amounts of procoagulant factors must be generated during a limited period of time when the VIIa/TF complex is active. The regulation of tissue factor exposure and activity is crucial to controlling initiation of coagulation. Even though platelets provide the major procoagulant surface for hemostasis, they do not express tissue factor and, therefore, cannot initiate the process. Activated coagulation factors produced at the site of VIJa/TF activity must find their way to the platelet surface to effectively propagate coagulation. Thus, induction of coagulation by tissue factor is a complex process. Its success or failure is governed by spatial, temporal, and quantitative features of factor IXa and factor Xa generation (ie, where, when, and how much factor is activated).
was only required for thrombin generation. We conclude that VllafTF-activatedfactors IXa and Xa have distinct physiologic roles. The main role of factor Xa that is initially activated by Vlla/TF is t o activate platelets by generating an initial, small amount of thrombin in the vicinity of platelets. Factor IXa, on the other hand, enhances thrombin generation by providing factor Xa on the platelet surface, leading to prothrombinase formation. Only tiny amounts of factors IX and X need t o be activated by Vlla/TF t o perform these distinct functions. Our experiments show that initiation of coagulation is highly dependent on activation of small amounts of factors IXa and Xa in proximity t o platelet surfaces and that these factors play distinct roles in subsequent events, leading t o an explosion of thrombin generation. Furthermore, the specific roles of factors IXa and Xa generated by Vlla/TF are not necessarily reflected by the kinetics of factor IXa and Xa generation. The relative significance of factor IX and factor X activation by the tissue factor pathway is currently unclear. Factor IX is clearly essential for normal hemostasis, but it can potentially be activated by at least two mechanisms: VIIa/TF (extrinsic pathway) and factor XIa (intrinsic pathway). There is also a putative platelet factor XI-like molecule that can activate factor IX.'.'j Small amounts of factor IX are activated by a tissue factor-dependent mechanism under baseline (nonbleeding) condition^,^ but it is unknown whether factor IX activation by tissue factor is necessary for initiation of coagulation. Although the kinetic parameters of factor X and factor IX activation vary with the source of tissue factor,8.q VIIa/TF consistently activates more factor X than IX under steady-state conditions.'" However, the amounts of the two factors activated at steady state may not be an indication of their relative physiologic importance. A more complete understanding of the initiation of coagulation can be gained by considering the interactions of the activated factors with the cells on which they are produced and on which they act to propagate coagulation. The effect of plasma protease inhibitors on the process is also likely to be substantial.
The goal of the current study was to examine the relative roles of tissue factor-generated factors IXa and Xa in the explosive burst of thrombin generation on platelets that leads to fibrin formation. We examined platelet activation and thrombin generation in two types of experiments. In one type of experiment, we incubated tissue factor-bearing monocytes in the presence of plasma levels of purified zymogen coagulation factors (11, V, VIII, IX, and X), TFPI, antithrombin 111 (AT), and unactivated platelets with catalytic amounts of activated factor VIIa. This complete system was designed to mimic tissue factor-initiated coagulation in vivo.
[t contained cell-associated tissue factor to initiate coagulation, platelets to provide the surface on which large-scale thrombin generation occurs, all the proteins necessary to assemble the Xase and prothrombinase complexes, and the relevant protease inhibitors. Platelet activation and thrombin generation in this system were also measured when either factor IX or factor X was omitted. In the second type of experiment, we added purified factor IXa or factor Xa to activated or unactivated platelets suspended in a mixture of purified zymogen coagulation factors, TFPI, and AT. In the latter experimental design, coagulation was initiated by the addition of specific amounts of preactivated factors IX and/ or X, rather than allowing tissue factor to activate them. This experimental design allowed us to isolate the effects of factors IXa and Xa on platelet activation and thrombin generation.
In our system, platelet activation always preceded thrombin generation. The addition of preactivated factor X efficiently promoted platelet activation but led to a relatively small amount of subsequent thrombin generation. Preactivated factor IX was an order of magnitude less potent than factor Xa in inducing platelet activation, but once platelet activation had occurred, factor IXa was much more effective than factor Xa at promoting thrombin generation. Omission of factor X from a VIIaiTF-initiated system (containing tissue factor-bearing cells, small amounts of factor VIIa, unactivated platelets, and plasma levels of zymogen factors 11, V, VIII, IX, and X) eliminated both platelet activation and thrombin generation. Omission of factor IX from this system (mimicking hemophilia B) dramatically reduced thrombin generation, while platelet activation occurred at a nearly normal rate. These experiments support the conclusion that factor Xa and factor IXa activated by VIIaiTF play different and distinct roles in initiating coagulation. The initial activation of factor X, which occurs before platelet activation, is more important for generating the first small amounts of thrombin required for platelet activation. Factor IX activation plays a major role in determining the rate of thrombin formation by activating factor X on the platelet surface, where it can assemble with factor Va into active prothrombinase complexes that lead to the ultimate explosion of thrombin generation.
MATERIALS AND METHODS

Materials.
Dulbecco's modified Eagle's medium (DMEM) was purchased from GIBCO (Grand Island, NY). Chromozyme TH was purchased from Boehringer-Mannheim (Indianapolis, IN). Spectrozyme FXa and TenStop were purchased from American Diagnostica (Greenwich, CT). Recombinant hirudin was purchased from Accurate Chemical and Scientific Corp (Westbury, NY). Antihuman factor X and antihuman factor IX polyclonal rabbit antibodies were purchased from Dako Corporation (Carpenteria, CA). Anti-CD62 (phycoerythrin-conjugated) was purchased from Becton Dickinson (San Jose, CA). Mono-Poly Resolving Medium was purchased from Flow Laboratories, Inc. Lipopolysaccharide (LPS) from Escherichia coli was purchased from Sigma Chemical CO (St Louis, MO). All other chemicals were of high commercial grade.
Proteins. Prothrombin and factor IX were purified from human plasma as described previously." Factor X was purchased from Enzyme Research Laboratories (South Bend, IN), and factor V from Calbiochem Corporation (La Jolla, CA) or Haematologic Technologies (Essex Junction, VT). Factor VI11 was purchased from the University of North Carolina hospital pharmacy as Profilate (Alpha Therapeutics, Los Angeles, CA). Thrombin" and ATI3 were purified from human plasma as previously described. Prothrombin, factor X, and factor IX were treated with an inhibitor mixture (1 pmol/L tosylLysyl-chloromethyl ketone, tosyl-Phenyl-chloromethyl ketone, GluGly-Arg-chloromethyl ketone, Phe-Pro-Arg-chloromethyl ketone, and Phenyl-methyl-sulfonyl fluoride), followed by exhaustive dialysis to inactivate proteases in the zymogens. In addition to treatment with low-molecular-weight inhibitors, the zymogen proteases were incubated for 12 hours with AT at a concentration IO times that in plasma. The proteins were diluted to plasma concentration just before the experiment. Recombinant factor VIIa and recombinant TFPI were gifts of NOVO Nordisk (Gentofte, Denmark). Factors IXa and Xa were prepared from the respective zymogens as previously described.14 Briefly, factor IX was activated with factor XIa (Enzyme Research Laboratories), and factor X with purified coagulant protein from Russell's viper venom (Haematologic Technologies). The activated factors were repurified on Q-Sepharose with calcium chloride elution. '5 Cell isolation. Monocytes were purified on Ficoll-Hypaque density gradients from the blood of healthy volunteers. 16 The mononuclear cell band was collected and diluted in an equal volume of 13 mmoVL citrate (pH 7.4), 123 mmoVL NaCI, 33 mmol/L dextrose with 10 pmol/L prostaglandin E,. The nucleated cells were sedimented at lOOg for 5 minutes, and the platelet-containing supernatant was retained for gel filtration." The mononuclear cell-containing pellet was washed twice with cold calcium-free medium, and the resulting pellet was resuspended in DMEM with 1 mg/mL dextrose and no serum. Two thousand monocytes per well were plated in 96-well plates in DMEM containing 0.5 pg/mL bacterial LPS. The plates were incubated at 37°C in 5% CO, for 1 hour. Nonadherent cells were removed by washing three times with fresh DMEM. Fresh LPS-containing DMEM was added, and the cells were cultured for 18 hours. The LPS-treated monocyte monolayers (LPS-monocytes) were then washed three times with Tyrodes buffer (15 mmoVL HEPES, pH 7.4, 3.3 mmol/L Na,P04, 138 mmol/L NaCI, 2.7 mmoU L KCI, 1 mmol/L MgClz, 5.5 mmol/L dextrose) containing 1 mg/ mL bovine serum albumin (Tyrodeslalbumin) before being used in experiments. The adherent population after culture and washing consisted of greater than 95% monocytes, with less than 5% contamination with lymphocytes. Platelet contamination was from one to two platelets per monocyte. This level of contamination was quite low compared with the number of purified platelets added to reaction wells (<0.006% of the platelets added).
Platelets were separated from plasma proteins by gel-filtering the platelet-containing supernatant from the monocyte preparation over a 50-mL column of Sepharose CL-2B in Tyrodeslalbumin. The platelet preparations contained less than 0.1% contamination by leukocytes. Platelets were kept at 37°C until used. Platelet activation, defined as expression of the CD62 antigen (P-selectin, GMP-140). was measured by flow cytometry." Reproducibly, fewer than 10% of the platelets were activated by the isolation procedure.
Experimental assay system. The complete cell and protein system is a modification of one we have previously used to examine tissue factor-initiated procoagulant complex assembly on the platelet surface.19 Tissue factor-bearing monocytes were incubated with purified coagulation proteins or proteins and platelets for up to 16 minutes. The platelets, isolated from the same blood donor as the monocytes, were at a final concentration of 80,0OO/pL to 1 IO,OOO/pL. The final concentrations of proteins were selected to approximate plasma levels: factor X, 8 pglmL; factor IX, 4 pg/mL; factor VIII, 1 UlmL; factor V, 7 pg/mL; TFPI, 0.1 pglmL; and AT, 150 pg/mL. The concentration of prothrombin used, 50 pglmL, is at the lower limit of normal plasma concentrations for this factor. The reactions were initiated by the addition of factor VIla (0.01 pg/mL) and calcium (3 m m o a ) . In some experiments, either factor IX or factor X was omitted from the protein mixture incubated with monocytes and platelets. In these experiments, 100 pg/mL of rabbit polyclonal antifactor IX or anti-factor X (both from Dako Corp, Santa Barbara, CA) was included in the incubation mixture to inactivate any trace For personal use only. on August 30, 2017. by guest www.bloodjournal.org From of the omitted factor. Although the system is artificial, it was designed to mimic the initial in vivo coagulation reactions.
In other experiments, different amounts of activated factor IX and/ or factor X were added directly to a mixture of platelets, coagulation proteins, and inhibitors except factor VIIa. Once the proteins had been added to the platelets, samples were taken at timed intervals and assayed for thrombin activity and platelet activation. The amount of thrombin generated in any given set of experiments was a function of the individual whose cells were used in the experiments. In replicate experiments, the pattern of platelet activation and the relative amounts of thrombin generated with different treatments were consistent, even though the absolute amounts of thrombin generated were different for cells from different donors. Each figure shows data run in parallel from one individual and is representative of experiments using cells from other individuals.
Assays. For the assay of thrombin activity, 10-pL samples from the experimental wells were added to 90 pL of 0.45 m m o K Chromozyme TH, 30 pmoVL TenStop (sufficient to block the greatest amount of factor Xa produced in these experiments), 2.2 mmol/L EDTA, in 20 mmol/L HEPES (pH 7.4), 150 m m o K NaC1, 1 mgl mL albumin. The assay mixture was incubated for I3 minutes, then cleavage of the chromogenic substrate was terminated by addition of 100 pL of 20% acetic acid. The amount of active enzyme was related to the cleavage of the synthetic substrate (measured at 405 nm in a V,,, plate reader [Molecular Devices Corp, Menlo Park, CA]) by a standard curve made using purified thrombin.
For assays of platelet activation and factor X(a) binding, separate 8-pL samples from the reaction mixtures were removed and added to 30 pL of 2% paraformaldehyde in 20 mmoVL HEPES, 150 mmoll L NaCI, 3 mmol/L CaCI2. Platelets were fixed in paraformaldehyde for 30 minutes, then diluted in 5 v01 of Tyrodeslalbumin, and incubated for at least an additional 30 minutes. Platelet activation was assessed by measuring expression of the activation-specific alpha granule marker CD62.I8 Samples were stained with phycoerythrinconjugated anti-CD62 (final dilution, 150) for 30 minutes at 25°C. Relative factor X(a) binding was assessed as previously described." Briefly, the platelet samples were incubated for 30 minutes with a 1:200 dilution of antihuman factor X (Dako), washed once, then incubated for 30 minutes in a 1:30 dilution of fluorescein isothiocyanate (F1TC)-conjugated goat antirabbit IgG (Sigma). The samples were washed once with filtered phosphate-buffered saline (PBS) and resuspended in 0.5 mL PBS, and the mean fluorescence intensity was determined on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA).
The activation state of the platelet-bound factor X was determined by Western blot analysis. Samples were removed from the incubation mixtures, and the platelets were centrifuged through a layer of 10% sucrose with 3 mmol/L CaCI,, to separate free from bound ligand. The platelet pellets were resuspended in 20 pL of IO mmol/L EDTA to dissociate membrane-bound factors X and Xa. The platelets were sedimented in a microfuge, and the supernatant was added to an equal volume of sodium dodecyl sulfate (SDS)-containing sample buffer and boiled for 1 minute. The samples were separated by polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membranes on a Phastgel System (Pharmacia, Uppsala, Sweden). Factor X antigen was detected using the same polyclonal rabbit immunoglobulin used for the flow cytometric assays and a chemiluminescent horseradish peroxidase substrate (LumiGLO; Kirkegaard & Perry Laboratories, Gaithersburg, MD).
Activation of factor X and factor IX by tissue factor-bearing monocytes was assayed as follows. Factor X (8 pg/mL), factor VIIa (0.01 pglmL). and 100,000 monocytes per well were incubated together in 200 pL of 20 mmoVL HEPES (pH 7.4), 150 mmol/L NaCl (HBS) with 5 mmol/L CaClz. At timed intervals, 50-pL samples were removed from the supernatant and incubated with 1 mmolL Spectrozyme FXa in 20 mmoUL HEPES (pH 7.4). 150 mmol/L NaCI, 5 mmoVL EDTA. The rate of cleavage of Spectrozyme was compared with the rate measured for a standard curve using factor Xa of known concentration. The background was determined from a sample that did not include factor X with the monocytes. Similarly. plasma concentrations of factor IX (4 pglmL) were incubated with 0.01 pglrnL factor VIIa and 100,000 monocytes per well in 200 pL HBS with 5 mmol/L CaCI,. At timed intervals, 50-pL samples were removed from the supematant and incubated with 50 pL of 60 prnol/ L phospholipid vesicles (30% phosphatidylserine, 70% phosphatidylcholine), 5 nmol/L factor VlIIa (activated with thrombin that was neutralized with hirudin), 300 nmol/L factor X , and 3 mmoilL CaCI? (final concentrations). Cleavage of Spectrozyme was measured at 405 nm, and the rate was determined as the second order value in a polynomial fit to the data. This rate was compared with the rate measured for a standard curve using factor IXa of known concentration. The background was determined from a sample that did not contain factor IX with the monocytes. The standard curves for factors IXa and Xa were calibrated by active-site titration with AT. The concentration of AT had been determined by titration with active site-titrated thrombin.I4 "'
RESULTS
Platelet activation and thrombin generation in the tissue factor-initiated system. Platelets (IOO,OOO/pL final concentration) were incubated with tissue factor-bearing monocytes and plasma levels of purified prothrombin, factor X, factor IX, factor VIII, AT, TFPI, and a catalytic amount of factor VIIa.I9 Platelet activation, as measured by exposure of the alpha granule membrane protein CD62, began within about 2 minutes after the addition of calcium (Fig 1A) . However, in the absence of monocytes, very little platelet activation occurred. We have previously shown that platelet activation is dependent on the generation of small amounts of thrombin, because no platelet activation occurs in the absence of prothrornbin.lg
The time course of thrombin generation in the presence of platelets and monocytes was compared with thrombin generation in wells containing platelets alone or monocytes alone. As shown in Fig IB, very little thrombin generation occurred in wells containing the coagulation proteins and platelets only. However, in the presence of both monocytes and platelets, thrombin generation began after a 2-or 3-minute lag period followed by a rapid burst of thrombin generation. Monocytes alone did not support generation of significant amounts of thrombin (data not shown). No thrombin generation was observed in the absence of calcium or when monocytes and platelets were both omitted. In addition, when monocytes were preincubated with an anti-tissue factor antibody at concentrations that completely inhibited monocyte tissue factor activity," platelet activation and thrombin generation were nearly identical to that seen in the absence of monocytes.
Effect of factor IXa and factor Xa on platelet activation and thrombin generation. Once we had ascertained that platelet activation and thrombin generation were dependent on the presence of tissue factor-bearing monocytes in a complete system that included platelets and coagulation zymogens, we conducted experiments to determine whether the addition of low concentrations of purified factor IXa, factor Xa, or combinations of the two factors, could reproduce the effects of tissue factor on platelet activation and thrombin generation. Different concentrations of factors IXa and Xa were added to wells containing platelets, all the zymogen coagulation factors, inhibitors, and calcium. The effect of factors IXa and Xa on platelet activation is shown in Fig 2. We found that as little as 10 pmoUL factor Xa (0.008% of the plasma concentration of factor X) was sufficient to initiate platelet activation in the presence of the other zymogen coagulation factors (Fig 2, upper panel) . However, platelet activation did not occur when prothrombin was omitted from the mixtures. This suggests that small amounts of factor Xa promote platelet activation by activating prothrombin to 1797 thrombin in amounts too small to be detected in the supernatant. By contrast, l 0 pmol/L factor IXa (0.015% of the plasma IX concentration) had no detectable effect on platelet activation (Fig 2, lower panel) . Considerably higher concentrations of factor IXa were required to induce platelet activation. For example, addition of 100 pmoVL factor IXa resulted in 50% of the platelets being activated after about 10 minutes. The addition of 100 pmol/L factor Xa resulted in 50% of the platelets being activated after only 4 minutes, Neither factor IXa nor factor Xa directly activated platelets (data not shown). A number of different events occur during the process of platelet activation. The platelet activation marker we used, CD62, reflects secretion of alpha granule contents. Alpha granule release is relatively slow compared with other events, such as shape change, activation of glycoprotein IIbl IIIa, and surface exposure of phosphatidyl serine. Thus, while we did not directly measure exposure of procoagulant lipids, CD62 expression is a good indicator that the platelet surface has already undergone the transformation to a procoagulant state. In fact, we found that CD62 expression always preceded large-scale thrombin generation in our model system. Thus, we might expect that exogenous factor Xa would be more effective in promoting thrombin generation than factor IXa, because it is more effective at inducing platelet activation. To separate an effect on platelet activation from an effect specifically on thrombin generation, we measured the amount of thrombin generated when the platelets were activated before the addition of coagulation factors. Platelets were activated by incubation for 10 minutes with 50 pg/mL of a thrombin receptor agonist peptide (SFLLRN)," which has no proteolytic activity of its own. This concentration was more than sufficient to induce maximal CD62 expression. Zymogen coagulation factors I1 and V, inhibitors, and calcium were added to activated platelets. In addition, either factor Xa or factors IXa, VIII, and X were added. The zymogens were always added at concentrations approximating those in plasma as detailed in Materials and Methods, while the activated factors were added at varying, but miniscule, concentrations. As shown in Fig 3, the amount of thrombin generated on activated platelets to which 10 or 100 pmol/L factor IXa had been added (lower panel) was significantly greater than platelets to which 10 or 100 pmol/L factor Xa had been added (upper panel). This finding suggests that factor IXa, in the presence of zymogen coagulation factors, is more effective than the same amount of exogenous factor Xa at promoting thrombin generation. We hypothesized that this is because factor IXa, as part of the Xase complex, can continue to activate factor X and provide a source of platelet- 
Factor Xa
Western blot analysis of the effect of 100 pmol/L factor IXa on platelet-associated factors X and Xa. Platelets (1OO,OOO/pL) were incubated in wells containing plasma levels of prothrombin, TFPI, AT, and factors V, X, and V111; 3 mrnollL CaCI,; and 0, 10, or 100 pmol/L factor IXa. The gel shown is from platelets incubated with l00 pmol/L factor IXa. Samples were taken at the indicated times (S, seconds; m, minutes), and the platelets were centrifuged through sucrose. Bound factors were eluted from the platelets by the addition of EDTA. The eluates were subjected t o SDS-PAGE and Western blotting using anti-factor X antibody, as detailed in Materials and Methods. The major band of higher molecular weight has the same electrophoretic mobility as authentic factor X, while the band of slightly lower molecular weight has the same mobility as factor Xa. The supernatant sample (Super) was taken after a 16-minute incubation from the supernatant after the platelets had been sedimented. Samples in the absence of factor IXa were similar t o those shown at 30 seconds incubation and showed no change in the proportions of factors X and Xa over time. Samples from platelets incubated with 10 pmollL factor IXa showed a smaller increase in platelet-associated factor Xa than those incubated with 100 pmol/L factor IXa. The 30-second through 12-minute lanes and supernatant lane were run on the same gel, while the 16-minute sample was on a separate gel. The gels were transferred t o nitrocellulose, reacted with antibodies and substrate at the same time, and exposed t o the same piece of x-ray film. The 16-minute lane was cut out and pasted next t o the remaining lanes for this photograph. These data are representative of three experiments performed.
associated factor Xa to form prothrombinase complexes. To test this hypothesis, we also measured the amount of plateletassociated factor X(a) resulting from the addition of different amounts of exogenous factor IXa or Xa in the experiments detailed above. As shown in Fig 4, the addition of increasing amounts of factor IXa, in the presence of factors VI11 and X, resulted in increasing amounts of factor X antigen associated with the platelet surface, up to twice the amount of factor X bound in the absence of added factor IXa. The polyclonal antibody used in these studies does not distinguish between zymogen and activated factor X. However, the increase in platelet-associated factor X correlated with the rate of thrombin generation, suggesting that addition of factor IXa results in increased functional factor Xa on the platelets. The addition of increasing amounts of factor Xa was not reflected in a significant increase in thrombin generation or platelet-associated factor X, suggesting that much of the exogenous factor Xa was unable to reach the platelet surface, perhaps being bound by inhibitors.
We next examined the activation state of the plateletbound factor X(a) antigen. Platelets were activated with SFLLRN and then added to a mixture of zymogen coagulation factors 11, V, VIII, and X, as well as AT and TFPI. Different amounts of factor IXa were added, and timed samples were removed as in the experiments described above. These samples were immediately centrifuged through sucrose to separate free from platelet-bound factors, and then EDTA was added to the platelet pellets to dissociate bound factor X(a). The eluates were subjected to Western blot analysis. Initially, the great majority of platelet-associated factor X antigen was in the zymogen form. In the presence of added factor IXa, there was a progressive increase in the amount of activated factor X (Fig 5) . In the absence of factor IXa, there was no increase in the proportion of platelet-bound factor X in the activated form. Very little of the factor X in the supernatant was activated, and very little antigen was detected at a molecular weight consistent with factor XdAT complexes. Thus, both factor X and Xa are bound to activated platelets, but factor IXa promotes the progressive activation of factor X on platelet surfaces. The platelet-associated factor Xa could then be directly incorporated into prothrombinase complexes.
Factor IX and factor X activation on tissue factor-bearing monocytes. To measure how much factor X and factor IX was activated on the tissue factor-bearing monocytes, 100, OOO monocytes per well were incubated with factor VIIa, calcium, and plasma concentrations of either factor IX or X for 1 hour. The amount of each factor that had been activated was measured by activity assays. We calculated that the amount of the factors activated in 1 minute by the number of monocytes used in our experiments (2,000 per well) would result in no more than 10 pmoVL of each activated factor being transferred to the platelet suspensions.
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From Roles of factors IXa and Xu in a tissue factor-initiated model system. Finally, we returned to a tissue factor-initiated system to determine whether factor IX and factor X activated on a cell surface functioned similarly to exogenously added factors IXa and Xa. Tissue factor-bearing monocytes and platelets were incubated with the complete complement of coagulation proteins (AT, TFPI, factors 11, V, VIIa, VIII, IX, and X) and compared with incubation mixtures lacking either factor IX or factor X. Mixtures lacking factor X demonstrated neither platelet activation nor thrombin generation (Fig 6) . Mixtures lacking factor IX showed a nearly normal rate of platelet activation (upper panel) but only a very small amount of thrombin generation (lower panel). Thus, in a tissue factor-initiated system, factor X activation by the extrinsic pathway promotes platelet activation, while factor IX activation by VIIa/TF is required for optimal thrombin generation on the platelet surface.
DISCUSSION
The work described in this report was undertaken to investigate the relative roles of factor IX and factor X activation by tissue factor in the process of initiating coagulation. One of the unanswered questions in hemostasis is why a deficiency of factor IX or factor VIII can cause such a severe bleeding diathesis. These factors work together to form the platelet (intrinsic) Xase complex. However, the VIIdTF complex should be able, at least partially, to offset a deficiency of factor IX or VI11 by activating factor X itself. As factor IX is a competitive inhibitor of factor X activation by VIIdTF,'" one might expect tissue factor-dependent activation of factor X to be increased in a compensatory manner when factor IX is lacking. A number of investigators have addressed this problem by studying the kinetic features of factor IX and X activation by tissue factor.x,'".21-2' Others have suggested that VIIa/TF cannot compensate for a lack of factor IX because TFPI rapidly inactivates it once some factor Xa has been generated.26 However, kinetic studies of the activities of tissue factor and its inhibitor do not necessarily address questions related to the physiology of the system. Our studies were designed to look at the effects of the products of VIIa/TF activity on platelets and platelet surface coagulation complexes as a step toward determining whether factors IXa and Xa, activated by VIIa/TF, play distinct physiologic roles in the clotting process.
Our data suggest that factor IX and factor X activated by VIIdTF play distinct roles in coagulation. Exogenously added factor Xa efficiently promoted platelet activation, and, in a tissue factor-initiated system, factor X was required for platelet activation and thrombin generation. However, once platelets were activated, the amount of thrombin generated was not a function of the amount of exogenously added factor Xa. We conclude that factor X activation on a tissue factor-bearing cell leads to the generation of small amounts of thrombin, which then leads to platelet activation.
In contrast to the effects of factor Xa, exogenously added factor IXa had little ability to promote platelet activation. However, added factor IXa led to increasing amounts of factor Xa on the platelet surface, ultimately leading to a burst of thrombin generation. In our tissue factor-initiated model system, omission of factor IX allowed nearly normal platelet activation but only minimal thrombin generation. We conclude that factor IX activation is not required for platelet activation but is required for optimal thrombin generation. Our results suggest that this is because factor E a , in complex with factor VIIIa, provides an ongoing supply of factor Xa on the platelet surface for formation of the prothrombinase complex. Factor Xa added into the For personal use only. on August 30, 2017. by guest www.bloodjournal.org From fluid phase at the beginning of the reaction (as provided by VIIa/TF) is not as effective in generating thrombin as is factor Xa generated on the platelet surface by the factor IXaNma complex. There are probably at least two reasons for this. First, factor Va constitutes part of the platelet surface-binding site for factor Xa. Factor Xa that is formed by V I I m before platelets and factor Va are activated has no means of localizing on the platelet surface. Instead, this factor Xa remains in solution, where it is susceptible to inhibition by AT and TFPI. Second, factor Xa that is activated by the factor IXaNma complex on the activated platelet may remain localized on the platelet surface and move directly into complex with factor Va. This factor Xa formed by the platelet Xase remains protected from inhibitors and can most efficiently participate in formation of prothrombinase complexes. Thus, factor X activated by W d TF on monocytes, endothelial cells, or stroma is a poor substitute for factor X activated by the platelet factor IXaNma complex. This interpretation is consistent with the fact that factor X activated by Wa/TF does not substitute for a lack of platelet Xase activity in patients with hemophilia.
Kinetic studies have provided detailed information about the rates of factor IX and factor X activation by VIIa/TF. However, kinetic studies may not address the physiologic roles of factor IX and factor X activation in tissue factorinitiated hemostasis. Our current data, based on an in vitro model that reflects in vivo conditions, suggest that factors IXa and Xa generated by the tissue factor pathway play distinct and complementary roles, and that both are required for effective initiation of coagulation. Optimal thrombin generation is achieved only when both factor X and factor IX are activated by the VIIa/TF complex. Factor Xa promotes platelet activation, probably by activating small amounts of prothrombin. Factor IXa promotes rapid thrombin generation on the activated platelet surface by activating factor Xa, which can then be incorporated into the platelet surface prothrombinase complex.
